Global Drugs For Erectile Dysfunction Market

Electrophysiology devices and equipment are used in the diagnosis and treatment of heart rhythm disorders through electrical activity. The main product types in the electrophysiology devices and equipment are electrophysiology ablation catheters, electrophysiology diagnostic catheters, and electrophysiology lab systems. Electrophysiology ablation catheters measure the electrical activity of the heart and diagnose abnormal heart rhythm. The various monitoring devices involved are electrocardiograph (ECG), electroencephalograph (EEG), electrocorticography (ECoG), electromyography (EMG), electroretinographic (ERG), electrooculography (EOG), Holter monitoring devices, X-ray systems, imaging and 3D mapping systems, and diagnostic electrophysiology catheters that are used in indication analysis of atrioventricular nodal reentry tachycardia (AVERT), Wolff-Parkinson-white syndrome (WPW), atrial flutter, and atrial fibrillation. The various end-users of electrophysiology devices and equipment are used in hospitals, diagnostic centres, and clinics. The electrophysiology devices and equipment market research report is one of a series of new reports from The Business Research Company that provides electrophysiology devices and equipment market statistics, including electrophysiology devices and equipment industry global market size, regional shares, competitors with a electrophysiology devices and equipment market share, detailed electrophysiology devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the electrophysiology devices and equipment industry. This electrophysiology devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global electrophysiology devices and equipment market size will grow from $5.43 billion in 2022 to $5.94 billion in 2023 at a compound annual growth rate (CAGR) of 9.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The electrophysiology devices and equipment market size is expected to grow to $8.07 billion in 2027 at a CAGR of 7.9%. An increase in the prevalence rate of cardiovascular diseases (CVD) forms one of the major drivers for the industries operating in the electrophysiology devices and equipment market. CVD cases remain the leading cause of death across the globe, which increases the demand for a quick and effective treatment of the disease, thus increasing the demand for electrophysiology devices. According to the Centers for Disease Control and Prevention (CDC), in 2020, 697,000 people died from heart diseases which was almost 1 in every 5 deaths. By 2030, 12.1 million people in the United States will suffer from atrial fibrillation, which is the most common type of heart arrhythmia. Lack of uniformity in the regulations governing the electrophysiology devices and equipment industry sometimes restricts the companies in the market from expanding globally, thereby hampering the market’s growth. The impact of individual country regulatory requirements can have huge implications for the availability of new electrophysiology devices and equipment. According to regulations in a few geographies, the manufacturers are required to conduct clinical trials (premarket and/or post-market) be either in whole or in part within a country. However, in markets such as Brazil, Japan, India, and China where local regulations are still in the nascent stage, the cost to run the trials is incurred by the manufacturers. For example, trials for devices like cardiac rhythm management (CRM) in multiple countries have less merit and do not reflect the true test results as it becomes difficult for the manufacturers to provide sufficient devices to run tests. To increase the profit margins and sales, the companies operating in the Electrophysiology (EP) devices and equipment industry are coming up with new technologies aimed towards improving EP mapping and localization technology. EP mapping is a procedure used to diagnose the origins of abnormal heart rhythms. This procedure uses an electrically sensitive catheter. With improved mapping technologies it becomes easy to detect and locate abnormalities in the heart. For example, in June 2020, Boston Scientific launched its DIRECTSENSE™ technology for monitoring the effect of radiofrequency energy delivery during the cardiac ablation procedure. The Reuse of a single-use device (SUD) is permitted by The Medicines and Healthcare products Regulatory Agency (MHRA) may impact the electrophysiology devices and equipment market growth as few of the products within the market may be reused. The MHRA allows the reuse of electrophysiology catheters, however, the device should be adherent to the medical devices directive and should have a CE mark. The reuse or reprocessing of electrophysiology catheters by electrophysiology (EP) laboratories in the US help in reducing the costs of these devices and lessening the environmental burden of the discarded bio-waste materials. As there is no clear regulation on reuse in developing nations such as Africa., Asia, Eastern Europe, Central America, and South America, the electrophysiology devices and equipment market may face a few challenges. In September 2021, Boston Scientific, a company operating in electrophysiology devices and equipment acquired Lumenis for a deal amount of $1.07 billion. With this acquisition, Boston scientific company expands its portfolio in the US and Japan. Lumenis is a medical equipment company and a technology company based in Israel. Major players in the electrophysiology devices and equipment market are St. Jude Medical, Boston Scientific Corporation, Abbott Laboratories, GE Healthcare, Philips Healthcare, Biotronik SE & Co. KG, Medtronic Inc., Biosense Webster, Microport Scientific Corporation, and Japan Lifeline Co. North America was the largest region in global electrophysiology devices and equipment market in 2022. Western Europe was the second-largest region in global electrophysiology devices and equipment market.The regions covered in the electrophysiology devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the electrophysiology devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The electrophysiology devices and equipment market consist of sales of ablation catheters, diagnostic catheters, mapping system, accessories, and other electrophysiology devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global electrophysiology devices and equipment market is segmented - 1) By Product Type: Electrophysiology Ablation Catheters, Electrophysiology Diagnostic Catheters, Electrophysiology Lab Systems 2) By Monitoring Device Type: Electrocardiograph (ECG), Electroencephalograph (EEG), Electrocorticograph (ECoG), Electromyograph (EMG), Electroretinograph (ERG), Electrooculograph (EOG), Holter Monitoring Devices, X-Ray Systems, Imaging and 3D Mapping Systems, Diagnostic Electrophysiology Catheters 3) By Indication Analysis: Atrioventricular Nodal Reentry Tachycardia (AVNRT), Wolff-Parkinson-White Syndrome (WPW), Atrial Flutter, Atrial Fibrillation 4) By End-Users: Hospitals, Diagnostic centers, Clinics

Neurostimulation devices are implantable and programmable medical devices that send low voltage electricity to a specific nerve or target in the spinal cord or brain to affect neuronal transmissions. This procedure is used to treat or modulate motor functions in conditions such as neuropathic pain, chronic pain, major treatment-resistant depression Parkinson’s disease, epilepsy, incontinence, gastroparesis, and essential tremor. The main products of the neurostimulation devices are implantable devices and external devices. The implantable devices involved are cochlear implants, deep brain stimulation; spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation, and gastric electric stimulation and the external devices are transcranial magnetic stimulation (TMS) and transcutaneous electrical nerve stimulation (TENS). The various applications of implantable devices are pain management, epilepsy, essential tremor, urinary and fecal incontinence, depression, dystonia, gastroparesis, and Parkinson's disease that are used by various end-users such as hospitals, rehabilitation centres, and medical clinics. The neurostimulation device market research report is one of a series of new reports from The Business Research Company that provides neurostimulation device market statistics, including neurostimulation device industry global market size, regional shares, competitors with a neurostimulation device market share, detailed neurostimulation device market segments, market trends and opportunities, and any further data you may need to thrive in the neurostimulation device industry. This neurostimulation device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global neurostimulation devices market size will grow from $5.69 billion in 2022 to $6.28 billion in 2023 at a compound annual growth rate (CAGR) of 10.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The neurostimulation devices market size is expected to grow to $9.04 billion in 2027 at a CAGR of 9.5%. The rising geriatric population across the globe is driving the growth of the neurostimulation device market. An increasing number of the population is aging, and this geriatric population is falling prey to different neurobiological disorders. For instance, according to the World Health Organization, in 2020 1 billion people in the world were 65 years and above. The number is expected to reach 1.4 billion by 2030 and 2.1 billion by 2050. The high cost associated with the neurostimulation Devices will impede the growth of the market. For example, the average price of neuromodulation devices for chronic pain management range from $13920 to $17940, and the average price of neuromodulation devices for epilepsy ranges from $25420 to $25970. Although the device construction between neurostimulation and cardiac rhythm management devices is similar, neuromodulation generators are 67 percent more expensive than cardiac rhythm management devices. Minimally invasive treatments are being developed for the treatment of various neurological disorders. The neurostimulation devices are being innovated in a way to cause minimum invasion during neurological treatments. For example, Deep Brain Stimulation (DBS) is a minimally invasive surgical procedure to treat neurological symptoms of Parkinson’s disease, including tremors, rigidity, and movement control. DBS uses a neurostimulation device, similar to a heart pacemaker, to deliver electrical pulses to a very precise location in the brain circuits that influence Parkinson’s disease symptoms. The electrical pulses from the DBS device block the activity of these circuits so the rest of the brain can function more normally. USFDA strictly regulates the approval of medical devices depending on their class which is based on the risk associated with the device. There is relatively few class I neurological devices. The majority of the neurological devices are classified under Class II and Class III. Class II devices include neurostimulators, aneurysm clips, and blood clot retrievers. Examples of Class III devices are deep brain stimulators and medical devices for the treatment of brain tumors. Approval of class III medical devices is complicated and requires clinical trials. The time taken for the trials can be 36 months or more, depending on the extent of clinical trials and additional information that the FDA might request. Also, the European Union has recently taken steps to strengthen its regulatory approval process significantly, and this is expected to delay approvals in Europe. The delay in regulatory approvals and the high cost of interventional devices are the major challenges faced by the companies involved in the manufacture of neurological devices. In 2020, Medtronic, an Irish medical device company has acquired Stimgenics for an undisclosed amount. This acquisition is expected to boost the chronic pain treatment portfolio of Medtronic. Stimgenics is a private company based in Bloomington, that is pioneered in new spinal cord stimulation (SCS) waveform known as Differential Target Multiplexed (DTM) spinal cord stimulation. After the completion of the acquisition, the new proprietary DTM SCS waveform will be available on the Medtronic Intellis Platform. Major players in the neurostimulation devices market are Medtronic, Cyberonics, Boston Scientific Corporation, St. Jude Medical, Nevro Corporation, Neuronetics Inc., NeuroPace Inc., NeuroSigma Inc., Cochlear Ltd., and NDI Medical. North America was the largest region in the global neurostimulation devices market in 2022. Asia-Pacific was the second-largest region in the neurostimulation devices market. The regions covered in global neurostimulation device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the neurostimulation devices market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The neurostimulation devices market consists of sales of spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global neurostimulation devices market is segmented - 1) By Product: Implantable Devices, External Devices 2) By Application: Pain Management, Epilepsy, Essential Tremor, Urinary and Fecal Incontinence, Depression, Dystonia, Gastroparesis, Parkinson's Disease 3) By End User: Hospitals, Rehabilitation Centers, Medical Clinic 4) By Implantable Devices: Cochlear Implants, Deep Brain Stimulation, Spinal Cord Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electric Stimulation 5) By External Devices: Transcranial Magnetic Stimulation (TMS), Transcutaneous Electrical Nerve Stimulation (TENS)

Neurodegenerative disorder therapeutics refer to a medication or gene therapy to treat patients with neurodegenerative disorders therapeutically by directly rectifying pathogenic pathways, through neuroprotection, neurorestoration, and symptom control. The main drug types of neurodegenerative disorder therapeutics are n- methyl- d- aspartate receptor, selective serotonin reuptake inhibitor, dopamine inhibitors, and others. Selective serotonin reuptake inhibitors are a type of medication that is commonly used to treat depression and a few other mental illnesses. The various indications include Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, Huntington’s disease, and other indications that ARE distributed through hospital pharmacy, retail pharmacy, and online pharmacy. The neurodegenerative disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides neurodegenerative disorder therapeutics market statistics, including neurodegenerative disorder therapeutics industry global market size, regional shares, competitors with a neurodegenerative disorder therapeutics market share, detailed neurodegenerative disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the neurodegenerative disorder therapeutics industry. This neurodegenerative disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global neurodegenerative disorder therapeutics market grew from $15.86 billion in 2022 to $17.14 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The neurodegenerative disorder therapeutics market is expected to grow from $23.65 billion in 2027 at a CAGR of 8.4%. Increased prevalence of neurodegenerative among the global population contributes to the growth of the neurodegenerative disorder therapeutics market. The increase in the geriatric population attributes to the increased prevalence of neurodegenerative disorders. According to World Population Prospects, the number of people above 60 years of age will increase to 2.1 billion in 2050 and it is expected that people aged over 80 years will triple to 425 million in 2050. According to the Alzheimer’s Association, around 5.8 million Americans are suffering from Alzheimer’s disease, and this number is projected to rise to around 14 million by 2050. The increased prevalence of neurodegenerative diseases among the aging population increases the demand for neurodegenerative disorder therapeutics thereby driving the market. High rates of failure in clinical trials and research and development (R&D) have always been a major challenge in the neurodegenerative disorder therapeutics market. Companies are continuously investing in R&D to develop treatments for neurodegenerative diseases but currently, very few treatments are approved for neurodegenerative disorders. According to a study in 2019, there are officially 112 new molecular entities in Alzheimer’s disease (AD) clinical trials, although there are 3558 in cancer trials. For instance, 12 of the 42 (28 percent) drugs certified by the US Food and Drug Administration (FDA) were oncology therapies, this compares with 0% of AD drugs in production. This failure entitled Alzheimer’s disease drugs to the highest rates of failure at 99.6% when compared to any other disease, including cancer, which has a failure rate of 81%. Moreover, as reported by The New England Journal of Medicine, no new drug has been approved by the Food and Drug Administration (FDA) to treat Alzheimer’s disease since 2013. The low rate of approval of neurodegenerative therapeutics hurts the market, hindering its growth of the market. Manufacturers of neurodegenerative disorder therapeutics are undergoing various strategic partnerships with government and non-government organizations to discover and develop therapeutics for a range of neurodegenerative diseases. The companies in the neurodegenerative disorder therapeutics market are also increasing their collaboration with other players in the market to increase their capabilities for research and development activities to develop new and more effective therapeutic solutions to treat neurodegenerative disorders. For instance, in July 2022, NRG Therapeutics, a UK-based drug discovery company focussed on therapeutic approaches, partnered with Domainex, a UK-based drug discovery service, to develop neurodegenerative disease treatment. For the treatment of Parkinson's disease, motor neurone disease (MND), and other incapacitating chronic neurodegenerative conditions, the firms would work together to develop novel small molecule disease-modifying medications. In January 2020, Biogen Inc., an American biotechnology company, paid $75 million for a novel clinical-stage asset, PF-05251749, as well as the applications from Pfizer.The acquisition of the asset is expected to strengthen Biogen’s existing pipeline of potential disease-modifying therapies in Alzheimer’s and Parkinson’s diseases since PF-05251749 is a CNS-penetrant regulator that has the potential to treat behavioural and neurological symptoms across various psychiatric and neurological diseases. Pfizer Inc. is a multinational pharmaceutical company based in the USA. Major players in the neurodegenerative disorder therapeutics market are Biogen, Pfizer, Novartis, Sanofi, Teva Pharmaceutical, UCB, Hoffmann- La Roche Ltd., ACADIA Pharmaceuticals Inc., Lundeck A/S, Boehringer Ingeiheim International GmbH, Merck Serono, Orion Pharma Ltd., Mitsubishi Tanabe Pharma America, Allergan, GlaxoSmith Kline PLC., AbbVie, Eli lilly, Celgene, Neuro- Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation, AstraZeneca, Alector, Yumanity Therapeutics, Yangtze River Pharmaceutical Group, Chongqing Zein Pharmaceutical and Eisai. North America was the largest region in the global neurodegenerative disorder therapeutics market in 2022. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the global neurodegenerative disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The neurodegenerative disorder therapeutics market includes revenues earned by entities by correction of pathogenic mechanisms, neuroprotection, neurorestoration, and symptom control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global neurodegenerative disorder therapeutics market is segmented - 1) By Indication Type: Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types 2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types 3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Brain and neuroimaging devices are medical devices used to capture the structure, function, or pharmacology of the brain and locate areas affected by neurological disorders. The main imaging types of brain and neuroimaging devices are functional magnetic resonance imaging (fMRI), computed tomography (CT), positron emission tomography (PET), electroencephalography (EEG), magnetoencephalography (MEG), and others. Positron emission tomography (PET) is a type of imaging technique that measures the metabolic activity of the cells of body tissues using radioactive substances. The various applications of brain and neuroimaging devices are Parkinson's disease, traumatic brain injury, epilepsy, dementia, sleep disorders, and other applications that are used in hospitals, diagnostic centers, and ambulatory surgical centers. The brain and neuroimaging devices market research report is one of a series of new reports from The Business Research Company that provides brain and neuroimaging devices market statistics, including brain and neuroimaging devices industry global market size, regional shares, competitors with a brain and neuroimaging devices market share, detailed brain and neuroimaging devices market segments, market trends and opportunities, and any further data you may need to thrive in the brain and neuroimaging devices industry. This brain and neuroimaging devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global brain and neuroimaging devices market size will grow from $35.49 billion in 2022 to $37.53 billion in 2023 at a compound annual growth rate (CAGR) of 5.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The brain and neuroimaging devices market size is expected to grow from $47.15 billion in 2027 at a CAGR of 5.9%. An increase in the incidence of neurological disorders is expected to drive the market. According to a report by the European Academy of Neurology, 1 in 3 people in 2022 are affected by a neurological disease and the number of deaths due to neurological disorders increased by almost 40% in the last 30 years. Brain and neuroimaging devices are used to diagnose neurological disorders increasing the survival rate and management of the disease. This increasing incidence rate is expected to drive the brain and neuroimaging devices market. The high cost of imaging devices is anticipated to hamper the market for brain and neuroimaging devices. Neurological and cognitive psychology research and design brain-computer interfaces require high-end machines such as Electroencephalography (EEG), Positron Emission Tomography (PET), Functional Magnetic Resonance Imaging (fMRI) among others. These are high-cost devices, for instance, the new 64-slice CT scanners range between $500,000 and $700,000, cost of a PETCT scanner ranges from $225,000 to $750,000, which is not affordable for all hospitals and labs, mainly in developing countries. Thus, the high cost of imaging devices hampers the buying capacity of hospitals and diagnostic labs, hampering the brain and neuroimaging devices market. Companies and researchers are focusing on developing portable brain scanners that are expected to revolutionize brain imaging by lowering the cost of devices, making them affordable and accessible to all. EMVision Medical Devices and researchers at Queensland University have developed a portable brain scanner technology that enables brain scanning to be performed at almost any location. Researchers at University College London have developed a portable MEG brain scanner that is lightweight, worn like just a helmet but can measure brain activity even as people make natural movements, providing improved imaging opportunities for patients with disorders that cause unprompted body movements, such as epilepsy. Major players in the brain and neuroimaging devices market are GE, Siemens, Philips, Canon, Hitachi Medical Systems, Medtronic PLC., EB Neuro S.p.A., Neurosoft, MinFound Medical Systems Co. Ltd., and Elekta. Western Europe was the largest region in the brain and neuroimaging devices market in 2022. North America was the second largest region in the global brain and neuroimaging devices market report. Africa. was the smallest region in the brain and neuroimaging devices market. The regions covered in the global brain and neuroimaging devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the brain and neuroimaging devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The brain and neuroimaging devices market consists of sales of imaging equipment for brain and nerves such as functional magnetic resonance imaging, computed tomography, positron emission tomography (pet), electroencephalography, magnetoencephalography, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales along the supply chain or as part of other products. The global brain and neuroimaging devices market is segmented - 1) By Imaging Type: Functional Magnetic Resonance Imaging (fMRI), Computed Tomography (CT), Positron Emission Tomography (PET), Electroencephalography (EEG), Magneto Encephalography (MEG), Other Imaging Types 2) By End-user: Hospitals, Diagnostic Centres, Ambulatory Surgical Centres 3) By Application: Parkinson’s Disease, Traumatic Brain Injury, Epilepsy, Dementia, Sleep Disorders, Other Applications

Brain monitoring refers to a set of continuous online monitoring, which substantially measures the particle velocity of cerebral blood flow and volume wave in the brain. Brain monitoring is used for individualized patient management such as brain and neuro-related diagnostics and treatment purposes. The main product types in brain monitoring are magnetoencephalography, electroencephalography, cerebral oximeters, functional magnetic resonance imaging (fMRI), intracranial pressure monitoring devices, and others. Magnetoencephalography refers to the noninvasive technique that detects and records the magnetic field associated with electrical activity in the brain. The procedures used are invasive and non-invasive. The applications involved are Parkinson’s disease, traumatic brain injury, epilepsy, dementia, sleep disorders, and others. The various end-users involved are hospitals and clinics, neurology centers, ambulatory surgery centers, diagnostic centers, and others. The brain monitoring market research report is one of a series of new reports from The Business Research Company that provides brain monitoring market statistics, including brain monitoring industry global market size, regional shares, competitors with a brain monitoring market share, detailed brain monitoring market segments, market trends and opportunities, and any further data you may need to thrive in the brain monitoring industry. This brain monitoring market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global brain monitoring market size grew from $6.7 billion in 2022 to $7.42 billion in 2023 at a compound annual growth rate (CAGR) of 10.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The brain monitoring market size is expected to grow to $10.12 billion in 2027 at a CAGR of 8.1%. The increasing incidence and prevalence of neurological disorders are expected to propel the growth of the brain monitoring market going forward. Brain monitoring is defined as the use of instrumentation for the evolution of a neurologic injury. Brain monitoring is used in neurological disorders to provide improved accuracy and reliability of information about the intensity of the neurologic injury. For instance, according to the World Health Organization (WHO) report, the worldwide occurrence of neurological health problems is expected to reach nearly 103 million by the year 2030. Therefore, the rising demand for increasing incidence and prevalence of neurological disorders is driving the growth of the brain monitoring market. Technological advancements have emerged as the key trend gaining popularity in the brain monitoring market. Major companies operating in the brain monitoring sector are focused on developing new technological solutions to strengthen their position. For instance, in June 2020, Researchers at the University of Helsinki created an artificial intelligence (AI) technique to analyze viewpoints and draw conclusions based on group brain activity, making testing more efficient and allowing devices to read images straight from the EEG. This infusion has a variety of applications such as clinical diagnostics, soft bioelectronics, wearable devices, and robotics which help the brain monitoring market grow worldwide. In October 2021, Brain Scientific Inc., a Florida-based neurology-focused medical device and software company, merged with Piezo Motion Corp. Through this merger, the company's entire market reach increased, and its capacity to launch novel disruptive products increased. Piezo Motion Corp. is a Florida-based innovator of high-precision motion technology. Major players in the market are Natus Medical Inc., Nihon Kohden Corporation, Philips Healthcare, GE Healthcare, Compumedics Ltd., Medtronic, Edwards Lifesciences Corporation, Advanced Brain Monitoring, Masimo Corporation, Spiegelberg GmbH & Co. KG, Cadwell Industries, Elekta A.B, Drägerwerk AG & Co. KGaA, and Electrical Geodesics. North America was the largest region in the brain monitoring market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the brain monitoring market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the brain monitoring market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The brain monitoring market includes revenue earned by entities by functional magnetic resonance imaging (FMRI), magnetoencephalography (MEG) and electroencephalography (EEG).The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global brain monitoring market is segmented - 1) By Product: Magnetoencephalograph, Electroencephalograph, Cerebral Oximeters, Functional Magnetic Resonance Imaging (fMRI), Intracranial Pressure Monitoring Devices, Other Product Types 2) By Procedure: Invasive, Non-invasive 3) By Application: Parkinson’s Disease, Traumatic Brain Injury, Epilepsy, Dementia, Sleep Disorders, Other Applications 4) By End User: Hospitals and Clinics, Neurology Centres, Ambulatory Surgery Centers, Diagnostic Centers, Other End Users

The dermatology drugs market consists of sales of dermatology drugs by entities (organizations, sole traders and partnerships) that produce dermatology drugs to treat skin diseases. This industry includes establishments that produce drugs to treat diseases such as rosacea, dermatitis, hyperhidrosis, androgenic alopecia, acne drugs, microbial infections and other skin disorders. The main types of dermatology drugs are acne drugs, dermatitis, psoriasis, and other drugs for dermatology diseases. Psoriasis is a skin condition that causes red, itchy scaly patches on the knees, elbows, trunk, and scalp. Hypolipidemic drugs are a diverse class of medications used to treat high levels of fats (lipids) in the blood, such as cholesterol (hyperlipidemia). The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global dermatology drugs market size is expected to grow from $49.55 billion in 2021 to $54.54 billion in 2022 at a compound annual growth rate (CAGR) of 10.1%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The dermatology drugs market is expected to reach $117.82 billion in 2026 at a CAGR of 21.2%. The dermatology drugs market was mainly driven by rapid growth in emerging markets in the historic period. Emerging markets growth was aided by rising disposable income, stable political environment and increasing foreign investments in these countries. For instance, according to the IMF, China’s GDP growth rate was 2.3% in 2020. Additionally, according to the World Economic Outlook Reports by the IMF, the global growth is 6% in 2021 and expected to be 4.4% in 2022. Thus, strong economic growth boosted the demand for dermatology drugs and this drove the market during the historic period. High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of dermatology drugs manufacturers. Drug manufacturing companies are using genome testing (genetic diagnosis) to reduce the time and costs spent in clinical trials. A clinical trial is a complex process and it often takes months for a drug to be available in the market. This deprives patients of cost-effective treatment. Researchers in the Rockefeller University used genomic testing and data analytics to predict the response of psoriasis patients for a given treatment. Genomic testing algorithms collect gene-expression data from skin biopsies and detect activity in 50,000 different genes. This technique can predict the response of a patient with an accuracy of 95% and within 12 weeks, thus saving significant time for clinical trials and the launch of new drugs. Major companies in the dermatology drugs market include Amgen, Reckitt Benckiser Group plc, AbbVie, Galderma S.A., LEO Pharma A/S, Bayer AG, GlaxosmithKline, Eli Lilly And Company, Novartis AG and Perrigo Company Plc. North America was the largest region in the dermatology drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the dermatology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global dermatology drugs market is segmented - 1) By Type: Acne Drugs, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The cardiovascular drugs market consists of sales of cardiovascular drugs by entities (organizations, sole traders and partnerships) that produce cardiovascular drugs to treat cardiovascular diseases. This industry includes establishments that produce anti-hypertensive drugs to prevent heart failure by controlling blood pressure and hypolipidemic drugs that reduce lipid and lipoprotein levels in the blood. It also consists of establishments which produce antithrombotic drugs to treat arterial and venous thrombosis. The main types of cardiovascular drugs market are anti-hypertensive drugs, hypolipidemics, anti thrombotics, and other drugs for cardiovascular diseases (congestive heart failure, anti-arrhythmic and anti-anginal drugs). Hypolipidemic drugs are a diverse class of medications used to treat high levels of fats (lipids) in the blood, such as cholesterol (hyperlipidemia). The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global cardiovascular drugs market size is expected to grow from $146.51 billion in 2021 to $153.60 billion in 2022 at a compound annual growth rate (CAGR) of 4.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cardiovascular drugs market is expected to reach $205.71 billion in 2026 at a CAGR of 7.6%. The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of cardiovascular diseases including hypertension. According to the World Health Organization, chronic disease prevalence is rose by 57% globally, in the year 2020. These factors are expected to increase the patient pool globally, thereby driving the cardiovascular drugs market during the forecast period. High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of cardiovascular drugs market manufacturers. NOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin. Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases. Use of NOACs makes it easier for patients to continue therapy post discharge as opposed to injections of Heparin and Warfarin which need medical assistance for administration. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb. Major companies in the cardiovascular drugs market include Medtronic Inc., Boston Scientific Corporation, Abbott Laboratories, Edwards Lifesciences, Cardinal Health, Inc., Johnson & Johnson, Terumo Corporation, Getinge Group, Teleflex Inc. and Becton Dickinson. North America was the largest region in the cardiovascular drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the cardiovascular drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cardiovascular drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global cardiovascular drugs market is segmented - 1) By Type: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs for Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic and Anti-Anginal Drugs) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The central nervous system (CNS) drugs market consists of sales of central nervous system drugs and related services by entities (organizations, sole traders and partnerships) that manufacture central nervous system drugs that are used in the treatment of diseases affecting the brain or spinal cord. The central nervous system integrates sensory information and instructs the body to respond accordingly. The spinal cord is a channel for signals between the brain and the rest of the body. CNS disorder is a condition in which the brain and spinal cord’s ability to function is affected, hence affecting the body. The market for CNS disorder drugs comprises of drugs that work in different ways depending on the type of disease by suppressing or boosting the brain activities The main types of central nervous system (CNS) drugs are analgesics, anti-parkinson drugs, anesthetics, anti-epileptics and other CNS drugs. Analgesics, also known as painkillers, are medications that alleviate various types of pain, ranging from headaches to injuries to arthritis. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global central nervous system drugs market size is expected to grow from $169.11 billion in 2021 to $178.70 billion in 2022 at a compound annual growth rate (CAGR) of 5.7%. The growth in the CNS drugs market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The central nervous system drugs market is expected to reach $264.97 billion in 2026 at a CAGR of 10.3%. The central nervous system drugs market will be driven by rapid growth in emerging markets in the forecast period. Emerging markets growth is aided by rising disposable income, stable political environment and increasing foreign investments in these countries. For instance, according to the IMF, China’s GDP growth rate was 2.3% in 2020., according to the World Economic Outlook Reports by the IMF, the global growth is 6% in 2021 and expected to be 4.4% in 2022. Thus, strong economic growth will boost the demand for central nervous system drugs and this will drive the market during the forecast period. During the forecast period, the growth of the central nervous system drugs market will be restrained by patent expiration of branded central nervous system drugs. In general, pharmaceutical companies invest a large sum of money in the drug development process and patents. During the patency period, the company holding the patent holds exclusivity for the manufacturing and distribution of drugs. Post expiration of patency, generic versions of the drugs are manufactured by other companies with prices much lower than the original branded drugs. Overall, this will negatively impact the growth of the market in terms of value. Many central nervous system drug manufacturers are collaborating with other manufacturers in the industry to share technical knowledge and improve product quality. These agreements are helping anti-epileptics drugs manufacturers broaden their products and services. For instance, in March 2021, SEQENS and Rondol Group had announced a collaboration in formulation research and continuous flow manufacturing for existing, repurposed, or new drugs for oncology, infectious diseases, and central nervous system disorders. In June 2021, DSM and Brains Bioceutical have established a global exclusive partnership to unlock the therapeutic potential of cannabinoids in early-stage drug development. The cannabinoid API market is rapidly expanding, fueled by strong scientific evidence demonstrating cannabinoid's potential in a variety of therapeutic areas, including Central Nervous System (CNS) diseases. Major companies in the central nervous system drugs market include Biogen Inc, Johnson & Johnson, Novartis AG, UCB S.A., Takeda Pharmaceuticals, AbbVie, Teva Pharmaceuticals, GlaxosmithKline, Daiichi Sankyo Company and H Lundbeck. North America was the largest region in the central nervous system drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the CNS drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the central nervous system drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global central nervous system drugs market is segmented - 1) By Type: Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Other CNS Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs